Chugai Enhances Kidney Disease Portfolio with Renalys Acquisition
Chugai has signed a definitive stock agreement to purchase Japan-based Renalys Pharma, expanding its kidney disease portfolio.
Through this acquisition, Chugai will secure exclusive rights to develop and market Renalys' sparsentan in South Korea, Japan, and Taiwan.
- Sparsentan is a dual endothelin and angiotensin II receptor antagonist.
- Initially developed by Travere Therapeutics, it has secured approval in Europe and the US to treat IgA nephropathy (IgAN).
- Renalys is currently progressing the oral therapy in the Japanese market.
The acquisition combines business intelligence and editorial excellence to reach engaged professionals across leading media platforms.
Author's summary: Chugai acquires Renalys to boost kidney disease portfolio.
More News
- Reflections on Intelligence, With Thomas Sowell and Justice Clarence Thomas
- Segregation High: The Hidden Failure of Massachusetts' Schools - Brown Political Review
- Our Sacred Right and Responsibility to Vote | New Jersey City University
- Claiming Freedom in Revolution and in War: an Introduction to the Anarchist Group in Sudan - Black Rose Anarchist Federation (2025)
- Misrata Youth and Revolutionaries Movement: Misratans who met Khaled Haftar represent only themselves